Finance

Immunotherapy company secures additional $4.1 million

Published in Hepatitis Weekly, February 6th, 2006

GlobeImmune, Inc., announced the final closing of a series B preferred stock financing. GlobeImmune added an additional $4.1 million to the previously announced first close of $34.3 million, bringing the total amount raised in the series B financing to $38.4 million.

New investors joining the series B round include PAC-LINK Bio Venture Capital, China Investment and Development (CIDC), and Yasuda Enterprise Development. The series B financing was led by Lilly Ventures and also included HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Medica Venture Partners, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners Healthcare, and GC&H...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry